Clinical Trials

Date: 2016-12-13

Type of information: Treatment of the first patient

phase: 2

Announcement: treatment of the first patient

Company: Zealand Pharma (Denmark)

Product: dasiglucagon (ZP4207)

Action mechanism: glucagon analog.  Dasiglucagon (ZP4207) is a glucagon peptide analog, invented and fully owned by Zealand and observed to have a favorable physical and chemical stability in liquid solution. In June 2016, dasiglucagon was proposed as an International Nonproprietary Name (pINN) for this product candidate.

Disease: type 1 diabetes

Therapeutic area: Metabolic diseases

Country: Germany

Trial details:

• The trial is a single-centre, randomised, sequential, cross-over trial assessing pharmacokinetic and pharmacodynamic responses after micro-doses of ZP4207 (dasiglucagon) administered subcutaneously to patients with type 1 diabetes mellitus under euglycaemic and hypoglycaemic conditions and compared to marketed glucagon. (NCT02916251)

Latest news: • On December 13, 2016, Zealand Pharma announced that the company has initiated a Phase IIa trial with the aim of assessing PK and PD responses after administration of the multiple-dose version of dasiglucagon in adult patients with type 1 diabetes. The first patients have been dosed. This Phase IIa trial is part of a program that has been designed to provide the foundation for longer clinical trials with the multiple-dose version of dasiglucagon in the dual-hormone artificial pancreas system. Results from the trial are expected in H1 2017.

Is general: Yes